Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.57 |
| ▸ | HTR1A | P08908 | 8/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28038757 | 0.88 | MEN1 (0.42) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5584542 | 0.82 | HTR2C (0.73) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27812820 | 0.82 | HTR2C (0.58) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25785425 | 0.81 | HTR2C (0.62) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5020033 | 0.81 | HTR1A (0.67) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22062953 | 0.79 | MEN1 (0.46) | HTR2CHTR1AHTR6 | |
| SCHEMBL25821804 | 0.78 | HTR2C (0.67) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24120164 | 0.78 | HTR2C (0.69) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL245508 | 0.78 | SLC6A2 (0.57) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19703083 | 0.77 | HTR2C (0.45) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468961-B1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-06-10 | — | — | EP | disclosed |
| EP-3468961-B1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-06-10 | — | — | EP | disclosed |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | GALAPAGOS NV (BE) | 2020-02-04 | — | — | US | disclosed |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | GALAPAGOS NV (BE) | 2020-02-04 | — | — | US | disclosed |
| US-20190300503-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-03 | — | — | US | disclosed |
| US-20190300503-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-03 | — | — | US | disclosed |
| WO-2017211667-A1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300503-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | ADAMTS5, ADAMTS4, ADAMTS1 | HTR2C 1172/4885HTR1A 530/4885SLC6A2 4484/4885 |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | ADAMTS5, ADAMTS4, ADAMTS1 | HTR2C 1171/4885HTR1A 615/4885SLC6A2 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.